# An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

> **NCT01483898** · PHASE3 · COMPLETED · sponsor: **Vericel Corporation** · enrollment: 41 (actual)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **BIOLOGICAL:** Ixmyelocel-T
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01483898
- **Lead sponsor:** Vericel Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-03-25
- **Final completion:** 2014-03-25
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01483898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01483898, "An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01483898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*